NCT01475851View on ClinicalTrials.gov

Phase 3 Study of GSK548470 in Patients With Compensated Chronic Hepatitis B With Poor Response to Other Drugs

PHASE3CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

June 30, 2013

Study Completion Date

October 31, 2014

Conditions
Hepatitis B, Chronic
Interventions
DRUG

GSK548470 300 mg tablet

Blue tablets containing 300 mg of tenofovir disoproxil fumarate

Trial Locations (11)

466-8560

GSK Investigational Site, Aichi

467-8602

GSK Investigational Site, Aichi

260-8677

GSK Investigational Site, Chiba

803-8505

GSK Investigational Site, Fukuoka

734-8551

GSK Investigational Site, Hiroshima

060-0033

GSK Investigational Site, Hokkaido

890-8520

GSK Investigational Site, Kagoshima

213-8587

GSK Investigational Site, Kanagawa

980-8574

GSK Investigational Site, Miyagi

105-8470

GSK Investigational Site, Tokyo

180-8610

GSK Investigational Site, Tokyo

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY